Kyntra Bio Inc (KYNB) vs NextCure, Inc. (NXTC)

Kyntra Bio Inc and NextCure, Inc. are both Biotechnology companies. Kyntra Bio Inc is the larger, with a market value of $28.3M against $25.4M — 1.1× the size. NextCure, Inc. has negative trailing earnings, so its P/E is not meaningful; Kyntra Bio Inc trades at 0.2×. Kyntra Bio Inc has the higher net margin (3,967.8% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Kyntra Bio Inc leads on 7 and NextCure, Inc. on 6.

Valuation

Metric KYNB NXTC Biotechnology median
P/E 0.15 n/m 7.88
P/S 6.08 0.99 11.47
P/B n/m 2.22 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 18.18 0.49 10.73
Earnings yield 652.74% (171.26%) (28.84%)
Free cash flow yield (135.59%) (138.87%) (23.03%)

Profitability

Metric KYNB NXTC Biotechnology median
Gross margin 6.28% 0.00% 65.16%
Operating margin (1,089.78%) 0.00% 0.00%
Net margin 3,967.77% 0.00% 0.00%
Free cash flow margin (824.19%) 0.00% 0.00%
Return on equity (157.83%) (195.22%) (57.72%)
Return on assets 131.26% (121.60%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric KYNB NXTC Biotechnology median
Revenue growth (TTM) (37.15%) — 5.64%
EPS growth (last fiscal year) 478.08% 17.75% —
Revenue growth, 5-year CAGR (48.42%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KYNB NXTC Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.69 3.47 4.73
Net debt to EBITDA 1.97 0.75 0.96

Dividend

Metric KYNB NXTC Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric KYNB NXTC Biotechnology median
Market cap 28.34m 25.36m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack